Additionally, a STING agonist (di-ABZI) and IDO inhibitor (1-methyl-d-tryptophan or 1-MT) combination inhibits tumor progression in the murine CRC via recruiting CD8+T cells and DCs and inhibiting immunosuppressive MDSCs (Table 1) [201]. Here, IDO1 is linked to neoplasm.